[Optimisation of treatment of Parkinson's disease with levodopa].
This article presents the major strategies for individualisation and optimisation of levodopa therapy. The relationship between pharmacokinetic and pharmacodynamic effects of levodopa is discussed. Pharmacokinetic parameters in different stages of Parkinson's disease are interpreted. Moreover, the main differences in pharmacokinetics of levodopa formulations and routes of administration are presented. The authors also suggest methods to increase efficacy and safety of levodopa therapy in patients with Parkinson's disease.
Białecka
Monika
M
Zakład Farmakologii Doświadczalnej i Klinicznej, Katedra Farmakologii, Pomorska Akademia Medyczna w Szczecinie, Szczecin. monika-bialecka@post.pl
Adamiak
Urszula
U
Gawrońska-Szklarz
Barbara
B
D000978:Antiparkinson Agents / Q000008:administration & dosage* / Q000493:pharmacokinetics; D018491:Dopamine Agonists / Q000008:administration & dosage* / Q000493:pharmacokinetics; D004305:Dose-Response Relationship, Drug; D005746:Gastric Emptying / Q000502:physiology; D006801:Humans; D007980:Levodopa / Q000008:administration & dosage* / Q000493:pharmacokinetics; D009043:Motor Activity / Q000187:drug effects; D010300:Parkinson Disease / Q000188:drug therapy*
D000978:Antiparkinson Agents; D018491:Dopamine Agonists; D007980:Levodopa